Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial

著者: Michael G. Hanna, Umesh A. Badrising, Olivier Benvéniste, Thomas E. Lloyd, Merrilee Needham, Hector Chinoy, Masashi Aoki, Pedro Machado, Christina Liang, Katrina Reardon, Marianne de Visser, Dana P. Ascherman, Richard J. Barohn, Mazen M. Dimachkie, James Miller, John T. Kissel, Björn Oskarsson, Nanette C. Joyce, Peter Van den Bergh, Jonathan Baets, Jan De Bleecker, Chafic Karam, William S. David, Massimiliano Mirabella, Sharon Nations, Hans H. Jung, Elena Pegoraro, Lorenzo Maggi, Carmelo Rodolico, Massimiliano Filosto, Aziz Shaibani, Kumaraswamy Sivakumar, Namita Goyal, Madoka Mori‐Yoshimura, Satoshi Yamashita, Naoki Suzuki, Masahisa Katsuno, Kenya Murata, Hiroyuki Nodera, Ichizo Nishino, Carla D Romano, Valerie Williams, John Vissing, Lixin Zhang Auberson, Min Wu, Ana de Vera, Dimitris A. Papanicolaou, Anthony A. Amato - The Lancet 2019 被引用: 133